The  	The  	 DT	O
future  	future  	 NN	O
of  	of  	 IN	O
sublingual  	sublingual  	 FW	B-NP
immunotherapy  	immunotherapy  	 FW	I-NP
Sublingual  	Sublingual  	 FW	I-NP
immunotherapy  	immunotherapy  	 FW	I-NP
( 	( 	 -LRB-	O
SLIT 	SLIT 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
currently  	currently  	 RB	O
the  	the  	 DT	O
most  	most  	 RBS	O
prescribed  	prescribed  	 JJ	O
form  	form  	 NN	O
of  	of  	 IN	O
allergen  	allergen  	 JJ	B-NP
immunotherapy  	immunotherapy  	 NN	I-NP
in  	in  	 IN	O
many  	many  	 JJ	O
European  	European  	 JJ	O
countries 	countries 	 NNS	O
.  	.  	 .	O
Its  	Its  	 PRP$	O
use  	use  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
accepted  	accepted  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
international  	international  	 JJ	O
consensus  	consensus  	 NN	B-NP
publications 	publications 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
recently  	recently  	 RB	O
also  	also  	 RB	O
the  	the  	 DT	O
scepticism  	scepticism  	 NN	O
of  	of  	 IN	O
USA  	USA  	 NNP	B-NP
scientists  	scientists  	 NNS	I-NP
is  	is  	 VBZ	O
attenuated 	attenuated 	 VBN	O
.  	.  	 .	O
Still 	Still 	 RB	O
,  	,  	 ,	O
this  	this  	 DT	O
treatment  	treatment  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
improved 	improved 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
possible  	possible  	 JJ	O
developments  	developments  	 NNS	B-NP
consist  	consist  	 VBP	O
of  	of  	 IN	O
modification  	modification  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
materials 	materials 	 NNS	O
,  	,  	 ,	O
use  	use  	 NN	O
of  	of  	 IN	O
adjuvants  	adjuvants  	 NN	B-NP
and  	and  	 CC	O
use  	use  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 JJ	O
allergens 	allergens 	 NN	O
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
new  	new  	 JJ	O
applications  	applications  	 NNS	B-NP
of  	of  	 IN	O
SLIT 	SLIT 	 NNP	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
food  	food  	 NN	B-NP
allergy 	allergy 	 NN	I-NP
,  	,  	 ,	O
seem  	seem  	 VBP	O
promising 	promising 	 VBG	O
.  	.  	 .	O
Concerning  	Concerning  	 VBG	B-NP
materials 	materials 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
future  	future  	 JJ	O
form  	form  	 NN	O
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
is  	is  	 VBZ	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
represented  	represented  	 VBN	O
by  	by  	 IN	O
tablets 	tablets 	 NNS	O
,  	,  	 ,	O
which  	which  	 WDT	O
were  	were  	 VBD	O
already  	already  	 RB	O
tested  	tested  	 VBN	O
for  	for  	 IN	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
with  	with  	 IN	O
grass  	grass  	 JJ	O
pollen  	pollen  	 NN	O
extracts 	extracts 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
are  	are  	 VBP	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
increase  	increase  	 VB	O
the  	the  	 DT	O
convenience  	convenience  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
patient  	patient  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
no-updosing  	no-updosing  	 JJ	B-NP
schedule 	schedule 	 NN	I-NP
.  	.  	 .	O
Adjuvants  	Adjuvants  	 JJ	B-NP
fitting  	fitting  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
characteristics  	characteristics  	 NN	O
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
seem  	seem  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
CpG  	CpG  	 JJ	B-NP
oligodeoxynucleotides  	oligodeoxynucleotides  	 NNS	I-NP
( 	( 	 -LRB-	O
CpG 	CpG 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
able  	able  	 JJ	O
to  	to  	 TO	O
interact  	interact  	 VB	O
with  	with  	 IN	O
the  	the  	 DT	O
Toll-like  	Toll-like  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
9  	9  	 CD	I-NP
( 	( 	 -LRB-	O
TLR9 	TLR9 	 NNP	B-NP
)  	)  	 -RRB-	O
whose  	whose  	 WP$	O
activation  	activation  	 NN	B-NP
induces  	induces  	 VBZ	O
a  	a  	 DT	O
Th1-like  	Th1-like  	 JJ	B-NP
pattern  	pattern  	 NN	I-NP
of  	of  	 IN	I-NP
cytokine  	cytokine  	 JJ	I-NP
release 	release 	 NN	I-NP
,  	,  	 ,	O
combination  	combination  	 NN	O
of  	of  	 IN	O
1,25-dihydroxyvitamin  	1,25-dihydroxyvitamin  	 NNP	O
D3  	D3  	 NNP	O
plus  	plus  	 CC	O
dexamethasone  	dexamethasone  	 NNS	B-NP
( 	( 	 -LRB-	O
VitD3-Dex 	VitD3-Dex 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
Lactobacillus  	Lactobacillus  	 NNP	B-NP
plantarum 	plantarum 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
approach  	approach  	 NN	O
with  	with  	 IN	O
recombinant  	recombinant  	 JJ	O
allergens 	allergens 	 NN	O
,  	,  	 ,	O
named  	named  	 VBN	O
component-resolved  	component-resolved  	 JJ	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
offers  	offers  	 VBZ	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
to  	to  	 TO	O
tailor  	tailor  	 VB	O
immunotherapy 	immunotherapy 	 NNS	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
was  	was  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
two  	two  	 CD	O
randomized  	randomized  	 CD	O
trials  	trials  	 NNS	O
of  	of  	 IN	O
subcutaneous  	subcutaneous  	 JJ	B-NP
SIT  	SIT  	 NNP	O
( 	( 	 -LRB-	O
16-17 	16-17 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
while  	while  	 IN	O
studies  	studies  	 NNS	O
with  	with  	 IN	O
SLIT  	SLIT  	 NNP	O
are  	are  	 VBP	O
not  	not  	 RB	O
yet  	yet  	 RB	O
available 	available 	 JJ	O
.  	.  	 .	O
Regarding  	Regarding  	 VBG	B-NP
food  	food  	 NN	I-NP
allergy 	allergy 	 NN	I-NP
,  	,  	 ,	O
an  	an  	 DT	O
important  	important  	 JJ	O
controlled  	controlled  	 JJ	O
study  	study  	 NN	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
SLIT  	SLIT  	 NNP	O
with  	with  	 IN	O
hazelnut  	hazelnut  	 NN	B-NP
is  	is  	 VBZ	O
able  	able  	 JJ	O
to  	to  	 TO	O
increase  	increase  	 VB	O
patients  	patients  	 NNS	B-NP
tolerance  	tolerance  	 NN	I-NP
over  	over  	 IN	O
possible  	possible  	 JJ	O
reactions  	reactions  	 NNS	O
from  	from  	 IN	O
inadvertent  	inadvertent  	 JJ	O
assumption  	assumption  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
culprit  	culprit  	 NN	B-NP
food 	food 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
warrants  	warrants  	 NNS	O
for  	for  	 IN	O
further  	further  	 JJ	O
trials  	trials  	 NNS	O
with  	with  	 IN	O
other  	other  	 JJ	O
foods 	foods 	 NNS	O
.  	.  	 .	O
